FTSE 100 held back by AstraZeneca trial setback

FTSE 100 held back by AstraZeneca trial setback

The FTSE 100 closed down 16.59 points at 10,472.45.

AstraZeneca loses £20bn in value after major heart drug trial setback

AstraZeneca suffered one of its biggest market setbacks in years after disappointing trial results for a key heart disease drug wiped more t

AstraZeneca sees stock market value slump by more than £20bn after drug setback

The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.

London stocks mixed amid weak tech but FTSE 100 edges up

The FTSE 100 closed up 14.11 points, 0.1%, at 10,665.88.

London's FTSE 100 slips as Middle East tensions persist, AstraZeneca drags

Astrazeneca shares fall 9% after Wainua heart drug fails Phase 3 trial

Svensk-britiske Astrazeneca er havnet i modvind på børsen torsdag oven på et sæt skuffende resultater fra et fase 3-studie med hjertemidlet